Related Experiment Videos
Endothelin-1: a multifunctional molecule in cancer
K Grant1, M Loizidou, I Taylor
1Department of Surgery, Royal Free and University College London Medical School, UK.
British Journal of Cancer
|March 1, 2003
Summary
Endothelin-1 (ET-1), a vasoconstrictor peptide, is implicated in cancer development. Targeting the endothelin system may offer a new strategy for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Endothelin-1 (ET-1) is a potent vasoconstrictor peptide discovered in 1988.
- Emerging evidence suggests a significant role for ET-1 in the complex processes of cancer development (tumorigenesis).
Purpose of the Study:
- To review the scientific evidence linking ET-1 to tumorigenesis.
- To explore the specific roles of ET-1 in key cancer hallmarks.
- To discuss the therapeutic potential of modulating the endothelin system in cancer treatment.
Main Methods:
- Literature review of studies investigating ET-1 and cancer.
- Analysis of ET-1's involvement in cellular processes relevant to cancer progression.
- Evaluation of endothelin-system-targeted therapies.
Main Results:
- ET-1 is implicated in promoting cancer cell proliferation (mitogenesis).
- ET-1 influences cancer cell survival by affecting apoptosis (programmed cell death).
- The peptide plays a role in the formation of new blood vessels (angiogenesis) that feed tumors.
- ET-1 contributes to tumor cell invasion and the spread of cancer to distant sites (metastasis).
Conclusions:
- Endothelin-1 is a key mediator in multiple stages of tumorigenesis.
- Targeting the endothelin system presents a promising avenue for adjuvant cancer therapy.
- Further research into endothelin-system modulation could lead to novel anti-cancer strategies.